Asset Details
Do you wish to reserve the book?
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Do you wish to request the book?
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
2006
Overview
Previous studies have implicated intravitreal vascular endothelial growth factor A (VEGF-A) as a target for countering neovascularization and, therefore, age-related macular degeneration. This double-blind, controlled trial comparing ranibizumab, which neutralizes all isoforms of VEGF-A, with photodynamic therapy with verteporfin showed that ranibizumab was better able to retard the progression of predominantly classic neovascular age-related macular degeneration.
This trial comparing ranibizumab with photodynamic therapy with verteporfin showed that ranibizumab was better able to retard the progression of predominantly classic neovascular age-related macular degeneration.
Age-related macular degeneration is a leading cause of severe and irreversible vision loss in the developed world among people 50 years of age or older.
1
–
4
The neovascular form of the disease is characterized by the growth of abnormal, choroidal blood vessels beneath the macula, which causes severe loss of vision.
5
Two main patterns of choroidal neovascularization that are associated with age-related macular degeneration, as seen on fluorescein angiography, are classic (in which intensely bright fluorescence is seen in early phases of the angiogram and leaks in late phases) and occult (in which leakage is less intense and appears in . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Aging
/ Angiogenesis Inhibitors - administration & dosage
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Biological and medical sciences
/ Choroidal Neovascularization - drug therapy
/ Female
/ Humans
/ Macular Degeneration - drug therapy
/ Macular Degeneration - pathology
/ Male
/ Photosensitizing Agents - adverse effects
/ Photosensitizing Agents - therapeutic use
/ Porphyrins - adverse effects
/ Porphyrins - therapeutic use
